Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + SY-1425
|
DC2HLXJ
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
ABIRATERONE + SY-1425
|
DCN52PI
|
ABIRATERONE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
ABIRATERONE + SY-1425
|
DC26CJX
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
ABIRATERONE + SY-1425
|
DCUW77F
|
ABIRATERONE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
ABIRATERONE + SY-1425
|
DC1XX9N
|
ABIRATERONE
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
ABIRATERONE + SY-1425
|
DCWAY8F
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
ABIRATERONE + SY-1425
|
DC1M1C9
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
ABIRATERONE + SY-1425
|
DC6S94P
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
ABIRATERONE + SY-1425
|
DCAEKCR
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
ABIRATERONE + SY-1425
|
DC73WH3
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
ABIRATERONE + SY-1425
|
DCSCE32
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
ABIRATERONE + SY-1425
|
DC8K94B
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Amonafide + SY-1425
|
DC9H3DO
|
Amonafide
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Amonafide + SY-1425
|
DC4ULPP
|
Amonafide
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Amonafide + SY-1425
|
DC9IN3P
|
Amonafide
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Amonafide + SY-1425
|
DCV7YQD
|
Amonafide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Amonafide + SY-1425
|
DCXL28C
|
Amonafide
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Amonafide + SY-1425
|
DCD01T0
|
Amonafide
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Amonafide + SY-1425
|
DCNRE8R
|
Amonafide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Anastrozole + SY-1425
|
DCZLQU8
|
Anastrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Anastrozole + SY-1425
|
DC4XPSN
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Anastrozole + SY-1425
|
DCQ4I6V
|
Anastrozole
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Anastrozole + SY-1425
|
DCWHTX7
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Anastrozole + SY-1425
|
DCT65GT
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Anastrozole + SY-1425
|
DCZKAZY
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Anastrozole + SY-1425
|
DCN11GS
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Anastrozole + SY-1425
|
DC17PO3
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Anastrozole + SY-1425
|
DCDPON6
|
Anastrozole
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Anastrozole + SY-1425
|
DC4ZRAJ
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Anastrozole + SY-1425
|
DCNVP75
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Anastrozole + SY-1425
|
DC2NCOS
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Anastrozole + SY-1425
|
DCNEI8T
|
Anastrozole
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Anastrozole + SY-1425
|
DCTHLMQ
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Anastrozole + SY-1425
|
DCPG4PL
|
Anastrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Arfolitixorin + SY-1425
|
DCFHK26
|
Arfolitixorin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
BIO-300 + SY-1425
|
DCJHDKD
|
BIO-300
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Bleomycin + SY-1425
|
DCSPRGX
|
Bleomycin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Bleomycin + SY-1425
|
DCHM7B0
|
Bleomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Bleomycin + SY-1425
|
DCCPH30
|
Bleomycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Bleomycin + SY-1425
|
DCUUD8W
|
Bleomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Cabazitaxel + SY-1425
|
DCX1XS1
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCF5CKV
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCL69GJ
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCVDJ6Q
|
Cabazitaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Cabazitaxel + SY-1425
|
DCDXUEZ
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC7P54Z
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC5UWNF
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCSJYHZ
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCUYL3N
|
Cabazitaxel
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC3JC4U
|
Cabazitaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC3HIHL
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCD82CM
|
Cabazitaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCK05N1
|
Cabazitaxel
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC8AXGT
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCLT4H1
|
Cabazitaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCQS69I
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC0EZ50
|
Cabazitaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC8VA2B
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Cabazitaxel + SY-1425
|
DC4IIU3
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Cabazitaxel + SY-1425
|
DCBKMGH
|
Cabazitaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Cabazitaxel + SY-1425
|
DCEOQSM
|
Cabazitaxel
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Cabazitaxel + SY-1425
|
DCBG3DV
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Cabazitaxel + SY-1425
|
DC7KOX2
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Cabazitaxel + SY-1425
|
DC5L4VT
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Crizotinib + SY-1425
|
DCSBEG4
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Crizotinib + SY-1425
|
DCRCFMU
|
Crizotinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Crizotinib + SY-1425
|
DC4OIB1
|
Crizotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Dacarbazine + SY-1425
|
DCZVV6X
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Dacarbazine + SY-1425
|
DC63T1C
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Dacarbazine + SY-1425
|
DCG9M0P
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Dacarbazine + SY-1425
|
DCUX4W7
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Dacarbazine + SY-1425
|
DCP60R3
|
Dacarbazine
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Dacarbazine + SY-1425
|
DCQW3GW
|
Dacarbazine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Dacarbazine + SY-1425
|
DC0XDBZ
|
Dacarbazine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Dactinomycin + SY-1425
|
DCIUD4E
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Dactinomycin + SY-1425
|
DCNFOEW
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Dactinomycin + SY-1425
|
DCUXOTV
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Dactinomycin + SY-1425
|
DC55DXY
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Dactinomycin + SY-1425
|
DCN21WS
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Dactinomycin + SY-1425
|
DCKGMRQ
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Dactinomycin + SY-1425
|
DC168GN
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dactinomycin + SY-1425
|
DCQXDJH
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Dactinomycin + SY-1425
|
DCC5MD4
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Dactinomycin + SY-1425
|
DC0QJA8
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Dactinomycin + SY-1425
|
DCQJCIZ
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Dactinomycin + SY-1425
|
DCKSFV0
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Dactinomycin + SY-1425
|
DC5Z47D
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Dactinomycin + SY-1425
|
DCJ5Y9T
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Dactinomycin + SY-1425
|
DCYDGNI
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Dactinomycin + SY-1425
|
DC6QL1K
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Dactinomycin + SY-1425
|
DCNDPSH
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Dactinomycin + SY-1425
|
DCWBDYY
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Dactinomycin + SY-1425
|
DCEIA8M
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Dactinomycin + SY-1425
|
DCDO6FU
|
Dactinomycin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Dactinomycin + SY-1425
|
DCXME7S
|
Dactinomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Dactinomycin + SY-1425
|
DC9E3D9
|
Dactinomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Dactinomycin + SY-1425
|
DCS0N1N
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Dactinomycin + SY-1425
|
DCWMNXP
|
Dactinomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Dactinomycin + SY-1425
|
DCEY2UY
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Dexrazoxane + SY-1425
|
DC57KXY
|
Dexrazoxane
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Dexrazoxane + SY-1425
|
DCS7DJ2
|
Dexrazoxane
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Dexrazoxane + SY-1425
|
DCA03W0
|
Dexrazoxane
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Dexrazoxane + SY-1425
|
DCW2OML
|
Dexrazoxane
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
DFN-15 + SY-1425
|
DCGOOAU
|
DFN-15
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + SY-1425
|
DCYZOEB
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
DFN-15 + SY-1425
|
DCKFZ16
|
DFN-15
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
DFN-15 + SY-1425
|
DC53O5U
|
DFN-15
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
DFN-15 + SY-1425
|
DCEPIN8
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
DFN-15 + SY-1425
|
DCBL4FV
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Digitoxin + SY-1425
|
DCLQ4Z1
|
Digitoxin
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Epirubicin + SY-1425
|
DC1M0E6
|
Epirubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Epirubicin + SY-1425
|
DCDVFYZ
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Epirubicin + SY-1425
|
DCWBAM2
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Epirubicin + SY-1425
|
DCRUQ04
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Epirubicin + SY-1425
|
DCWUH8A
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Epirubicin + SY-1425
|
DCSTMJI
|
Epirubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Epirubicin + SY-1425
|
DC33ABV
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Epirubicin + SY-1425
|
DCKYM26
|
Epirubicin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Epirubicin + SY-1425
|
DCHDUAC
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Epirubicin + SY-1425
|
DCFTIYS
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Epirubicin + SY-1425
|
DCACHRW
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Epirubicin + SY-1425
|
DCS5CYD
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Epirubicin + SY-1425
|
DC5NMBO
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Epirubicin + SY-1425
|
DCIQLM3
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Epirubicin + SY-1425
|
DCQDMVT
|
Epirubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Epirubicin + SY-1425
|
DCRN0KO
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Epirubicin + SY-1425
|
DC3GDEX
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Gefitinib + SY-1425
|
DC47O85
|
Gefitinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Gefitinib + SY-1425
|
DCSC8VK
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Gefitinib + SY-1425
|
DC9A8E5
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Gefitinib + SY-1425
|
DCHM3OE
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Gefitinib + SY-1425
|
DCXVL5D
|
Gefitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Gefitinib + SY-1425
|
DCT6Y0B
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Gefitinib + SY-1425
|
DCISVSX
|
Gefitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Gefitinib + SY-1425
|
DCBC21J
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Indazole derivative 5 + SY-1425
|
DCEVVX6
|
Indazole derivative 5
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Indazole derivative 5 + SY-1425
|
DCV3P1T
|
Indazole derivative 5
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DC1T48L
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DCDPZ9D
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Indazole derivative 5 + SY-1425
|
DC0CYTT
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Indazole derivative 5 + SY-1425
|
DCJMRG8
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Indazole derivative 5 + SY-1425
|
DCR1ZDL
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
JNK-IN-8 + SY-1425
|
DCSOY7Y
|
JNK-IN-8
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
JNK-IN-8 + SY-1425
|
DCA31EE
|
JNK-IN-8
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Lenalidomide + SY-1425
|
DC8RGAV
|
Lenalidomide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Lenalidomide + SY-1425
|
DCZQ3QT
|
Lenalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Lenalidomide + SY-1425
|
DCG2BUY
|
Lenalidomide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Lenalidomide + SY-1425
|
DCTM58K
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Lenalidomide + SY-1425
|
DCDCI5I
|
Lenalidomide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Lenalidomide + SY-1425
|
DC8CHOL
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Lenalidomide + SY-1425
|
DC36V8A
|
Lenalidomide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Lenalidomide + SY-1425
|
DC49LTE
|
Lenalidomide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Letrozole + SY-1425
|
DCGR1K3
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Letrozole + SY-1425
|
DC8HJPP
|
Letrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Letrozole + SY-1425
|
DC58R1U
|
Letrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Letrozole + SY-1425
|
DCF2GUB
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
LIAROZOLE + SY-1425
|
DC1BW8G
|
LIAROZOLE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCFXASA
|
Mechlorethamine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Mechlorethamine + SY-1425
|
DCP1CG5
|
Mechlorethamine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Mechlorethamine + SY-1425
|
DCTI2GI
|
Mechlorethamine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Mechlorethamine + SY-1425
|
DCLN6UZ
|
Mechlorethamine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Mechlorethamine + SY-1425
|
DC4LPQP
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Mechlorethamine + SY-1425
|
DC7YHX2
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCLGHCC
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCH343O
|
Mechlorethamine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCX8JCU
|
Mechlorethamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCJ5RJM
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCYVPBH
|
Mechlorethamine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCT64U7
|
Mechlorethamine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Mechlorethamine + SY-1425
|
DC4FUXX
|
Mechlorethamine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Mechlorethamine + SY-1425
|
DCBFSEB
|
Mechlorethamine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Methotrexate + SY-1425
|
DC9DXF4
|
Methotrexate
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Methotrexate + SY-1425
|
DC5TNHP
|
Methotrexate
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Picoplatin + SY-1425
|
DCUQD9C
|
Picoplatin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Picoplatin + SY-1425
|
DCLIWEX
|
Picoplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Picoplatin + SY-1425
|
DCSARLZ
|
Picoplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Picoplatin + SY-1425
|
DC9ZSYU
|
Picoplatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Picoplatin + SY-1425
|
DC4CTNN
|
Picoplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Picoplatin + SY-1425
|
DCOUEIR
|
Picoplatin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + SY-1425
|
DCDZ9EU
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + SY-1425
|
DCEN7W2
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Ruxolitinib + SY-1425
|
DC1D4YS
|
Ruxolitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Ruxolitinib + SY-1425
|
DCITECP
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Ruxolitinib + SY-1425
|
DC84DFM
|
Ruxolitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Ruxolitinib + SY-1425
|
DCNJSBO
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Pentostatin
|
DCYBKX0
|
Pentostatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
SY-1425 + Pentostatin
|
DCMRBUI
|
Pentostatin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
SY-1425 + Fulvestrant
|
DCMBB1M
|
Fulvestrant
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Fulvestrant
|
DCS2ZVS
|
Fulvestrant
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Fulvestrant
|
DC9NP7P
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Fulvestrant
|
DCR298D
|
Fulvestrant
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Hepzato
|
DCGMUOJ
|
Hepzato
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Ixabepilone
|
DCKB2OG
|
Ixabepilone
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Panobinostat
|
DCOFH0H
|
Panobinostat
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SY-1425 + Isoniazid
|
DCI4Y6E
|
Isoniazid
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Isoniazid
|
DCGXGTN
|
Isoniazid
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Isoniazid
|
DCVA73C
|
Isoniazid
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Arsenic trioxide
|
DCUZ9FI
|
Arsenic trioxide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Plicamycin
|
DCS9RMN
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Plicamycin
|
DC798ED
|
Plicamycin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Plicamycin
|
DCJGGDS
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Plicamycin
|
DC9U88D
|
Plicamycin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Nilotinib
|
DCS19JV
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Triapine
|
DCB5W11
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + Triapine
|
DCQ8PEN
|
Triapine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + 10-hydroxycamptothecin
|
DCOCTM7
|
10-hydroxycamptothecin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + 10-hydroxycamptothecin
|
DCXM5N3
|
10-hydroxycamptothecin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Topetecan
|
DCWD7J7
|
Topetecan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Topetecan
|
DCAVXNM
|
Topetecan
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Topetecan
|
DCW8OER
|
Topetecan
|
Glioma (Cell Line: SF-539)
|
[2] |
|
SY-1425 + Terameprocol
|
DCUU5KG
|
Terameprocol
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
SY-1425 + Terameprocol
|
DCUQWIC
|
Terameprocol
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Terameprocol
|
DCHTK01
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Terameprocol
|
DCWDG2S
|
Terameprocol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Terameprocol
|
DC3O9QK
|
Terameprocol
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Terameprocol
|
DCI4FN3
|
Terameprocol
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + SCH 727965
|
DCEN33R
|
SCH 727965
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Ifosfamide
|
DCWCQ26
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Docetaxel
|
DC97CPL
|
Docetaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Docetaxel
|
DCS4I3S
|
Docetaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Docetaxel
|
DCABU9S
|
Docetaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
SY-1425 + Docetaxel
|
DC4ODWE
|
Docetaxel
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Docetaxel
|
DCKKJVP
|
Docetaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
SY-1425 + Docetaxel
|
DC9JMBK
|
Docetaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Docetaxel
|
DC5FDQ7
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Docetaxel
|
DCA2NMN
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SY-1425 + Docetaxel
|
DCG1TG7
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Docetaxel
|
DC6LL9E
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + Docetaxel
|
DCTEX0N
|
Docetaxel
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Docetaxel
|
DCWFJ67
|
Docetaxel
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SY-1425 + Docetaxel
|
DCJ4UFM
|
Docetaxel
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Docetaxel
|
DCIEM4V
|
Docetaxel
|
Glioma (Cell Line: SF-539)
|
[2] |
|
SY-1425 + Docetaxel
|
DC1F8HA
|
Docetaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Docetaxel
|
DCG235K
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SY-1425 + Docetaxel
|
DCUKN23
|
Docetaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Docetaxel
|
DC3LJXB
|
Docetaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
SY-1425 + Raloxifene
|
DC8PN8V
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Raloxifene
|
DCCHBKU
|
Raloxifene
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Marizomib
|
DCJY3UW
|
Marizomib
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[2] |
|
SY-1425 + Sirolimus
|
DCVYDUM
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Sirolimus
|
DCBCE1A
|
Sirolimus
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Sirolimus
|
DCND9UY
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SY-1425 + Sirolimus
|
DC3IJWZ
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Sirolimus
|
DC8E3D4
|
Sirolimus
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Sirolimus
|
DC06STC
|
Sirolimus
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SY-1425 + Sirolimus
|
DC12XZ9
|
Sirolimus
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Mitomycin
|
DCKFP0G
|
Mitomycin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
SY-1425 + Mitomycin
|
DC0CYUV
|
Mitomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Mitomycin
|
DCJ8C9O
|
Mitomycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Altretamine
|
DC3HT32
|
Altretamine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Altretamine
|
DC2M5RT
|
Altretamine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + TEM
|
DCSSUD1
|
TEM
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + TEM
|
DC8FGGC
|
TEM
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SY-1425 + Idarubicin
|
DCBFXXZ
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[2] |
|
SY-1425 + Imatinib
|
DC4IB4Y
|
Imatinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
SY-1425 + Imatinib
|
DCC5LYY
|
Imatinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Bortezomib
|
DC188M0
|
Bortezomib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Valrubicin
|
DC0CDNZ
|
Valrubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Valrubicin
|
DCBQJVD
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SY-1425 + Valrubicin
|
DC2JDXA
|
Valrubicin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Chlorambucil
|
DCM66MY
|
Chlorambucil
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Sorafenib
|
DCDIHX5
|
Sorafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Sorafenib
|
DCNEIOK
|
Sorafenib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Sorafenib
|
DCYS24P
|
Sorafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
SY-1425 + Sorafenib
|
DC8OJG7
|
Sorafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Sorafenib
|
DCWU39R
|
Sorafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Sorafenib
|
DCXTLIK
|
Sorafenib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + Sorafenib
|
DCBTQSW
|
Sorafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
SY-1425 + Sorafenib
|
DCIIU4G
|
Sorafenib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SY-1425 + Sorafenib
|
DCZWBTS
|
Sorafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + Sorafenib
|
DCNTFMT
|
Sorafenib
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Sorafenib
|
DCVYY74
|
Sorafenib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SY-1425 + Sorafenib
|
DCSWX52
|
Sorafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Sorafenib
|
DC5K1UA
|
Sorafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Pomalidomide
|
DCOHKL2
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SY-1425 + Pomalidomide
|
DCMNJGV
|
Pomalidomide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + Vinflunine
|
DCMXQGT
|
Vinflunine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Vinflunine
|
DCNMWLG
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Vinflunine
|
DC0ZOL9
|
Vinflunine
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Vinflunine
|
DC475S3
|
Vinflunine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
SY-1425 + Vinflunine
|
DCA69Z7
|
Vinflunine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + Vinflunine
|
DCIM8MA
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Vinflunine
|
DCKH99K
|
Vinflunine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Vinflunine
|
DCSXPKQ
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SY-1425 + Vinflunine
|
DCZ4DXJ
|
Vinflunine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
SY-1425 + Taxol
|
DCUHV1X
|
Taxol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
SY-1425 + Taxol
|
DC46IBE
|
Taxol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
SY-1425 + Taxol
|
DCEUG0B
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
SY-1425 + Taxol
|
DCTY9JT
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
SY-1425 + Taxol
|
DCK4XFJ
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + Taxol
|
DCDPXWY
|
Taxol
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Taxol
|
DCIJ8WD
|
Taxol
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Taxol
|
DC9FD1U
|
Taxol
|
Glioma (Cell Line: SF-268)
|
[2] |
|
SY-1425 + Taxol
|
DCGF0X1
|
Taxol
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Taxol
|
DCJMAX6
|
Taxol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
SY-1425 + Taxol
|
DCB5EZV
|
Taxol
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
SY-1425 + FORMESTANE
|
DCNCTYE
|
FORMESTANE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + FORMESTANE
|
DCYO3LA
|
FORMESTANE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
SY-1425 + FORMESTANE
|
DCWZGUJ
|
FORMESTANE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
SY-1425 + FORMESTANE
|
DCZZBPH
|
FORMESTANE
|
Glioma (Cell Line: SF-295)
|
[2] |
|
SY-1425 + Busulfan
|
DC65S4M
|
Busulfan
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
SY-1425 + Busulfan
|
DCG5IXA
|
Busulfan
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
SY-1425 + Dasatinib
|
DC7AK94
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
SY-1425 + Pentostatin
|
DCN7ATE
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Fulvestrant
|
DCHQMHM
|
Fulvestrant
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
SY-1425 + Fulvestrant
|
DCG1BA6
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + Fulvestrant
|
DCHP05W
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Dactinomycin
|
DCNXQAW
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + PMID28460551-Compound-2
|
DCIHNRU
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Arsenic trioxide
|
DCOINMX
|
Arsenic trioxide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Nilotinib
|
DCPCYTY
|
Nilotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SY-1425 + Triapine
|
DCX8AJH
|
Triapine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
SY-1425 + Pralatrexate
|
DC8I02X
|
Pralatrexate
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
SY-1425 + Terameprocol
|
DCKS5JY
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Docetaxel
|
DC6Y8EZ
|
Docetaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SY-1425 + Docetaxel
|
DCEY78C
|
Docetaxel
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
SY-1425 + Docetaxel
|
DCVPKK3
|
Docetaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
SY-1425 + Docetaxel
|
DC9GUBY
|
Docetaxel
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
SY-1425 + Docetaxel
|
DCLEGSI
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + Docetaxel
|
DCSOMJB
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Docetaxel
|
DC23Z7Y
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Sirolimus
|
DCV2VN6
|
Sirolimus
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SY-1425 + Sirolimus
|
DCCRUIC
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + Sirolimus
|
DCU3MGL
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Mitomycin
|
DCQEAK4
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + TEM
|
DC2X2FE
|
TEM
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
SY-1425 + TEM
|
DCUPKHT
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Imatinib
|
DC1R6F0
|
Imatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SY-1425 + Imatinib
|
DC7MNHT
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Bleomycin
|
DCJ8WMW
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Valrubicin
|
DCFKA4U
|
Valrubicin
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
SY-1425 + Valrubicin
|
DCCJL8D
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + Chlorambucil
|
DCV57AF
|
Chlorambucil
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
SY-1425 + Chlorambucil
|
DCSYR34
|
Chlorambucil
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + Sorafenib
|
DCDRAJT
|
Sorafenib
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
SY-1425 + Sorafenib
|
DCT06GQ
|
Sorafenib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
SY-1425 + Sorafenib
|
DC8LVNY
|
Sorafenib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
SY-1425 + Sorafenib
|
DCKHLWP
|
Sorafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Vinflunine
|
DC8N5UQ
|
Vinflunine
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
SY-1425 + Vinflunine
|
DCGHHUF
|
Vinflunine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
SY-1425 + Vinflunine
|
DCWKSPV
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Taxol
|
DC4WN0A
|
Taxol
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SY-1425 + Taxol
|
DC60YAW
|
Taxol
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
SY-1425 + Taxol
|
DCSZ8BO
|
Taxol
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
SY-1425 + Taxol
|
DCQP3LK
|
Taxol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
SY-1425 + Taxol
|
DCAMS9D
|
Taxol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
SY-1425 + Taxol
|
DCK989Q
|
Taxol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
SY-1425 + FORMESTANE
|
DCQ2LX2
|
FORMESTANE
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
SY-1425 + Pentostatin
|
DCOIA4L
|
Pentostatin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Fulvestrant
|
DCAL07K
|
Fulvestrant
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Fulvestrant
|
DC1WTFM
|
Fulvestrant
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Fulvestrant
|
DCIMQH4
|
Fulvestrant
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SY-1425 + Fulvestrant
|
DCV5FVJ
|
Fulvestrant
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
SY-1425 + Fulvestrant
|
DCHJG58
|
Fulvestrant
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Hepzato
|
DC2VJ7T
|
Hepzato
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Hepzato
|
DC4BELG
|
Hepzato
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Ixabepilone
|
DC1R8H9
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Ixabepilone
|
DC6BDLS
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Ixabepilone
|
DCS7K5U
|
Ixabepilone
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
SY-1425 + Ixabepilone
|
DCBE2A9
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Ixabepilone
|
DC3ZNQG
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Ixabepilone
|
DCDX2SK
|
Ixabepilone
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Lapatinib
|
DC5ZACX
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Cyclophosphamide
|
DCL2VO0
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Cyclophosphamide
|
DCBCB0P
|
Cyclophosphamide
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Cyclophosphamide
|
DCDSMTI
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Cyclophosphamide
|
DCM3Q7F
|
Cyclophosphamide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Isoniazid
|
DCBZ8GW
|
Isoniazid
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Isoniazid
|
DCCPNH1
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
SY-1425 + Arsenic trioxide
|
DCGWJE7
|
Arsenic trioxide
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Plicamycin
|
DC0GGED
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Plicamycin
|
DCBE4ES
|
Plicamycin
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Plicamycin
|
DC4JOOX
|
Plicamycin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Plicamycin
|
DCYBDGA
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Plicamycin
|
DCGOD7P
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Plicamycin
|
DCZYG5N
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Plicamycin
|
DC7IXDX
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Plicamycin
|
DC3C4I0
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Plicamycin
|
DCD05FH
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
SY-1425 + Plicamycin
|
DCYI6L3
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + Nilotinib
|
DC35SRQ
|
Nilotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Nilotinib
|
DCMY8DR
|
Nilotinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
SY-1425 + Nilotinib
|
DCXIA2A
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
SY-1425 + Triapine
|
DC9P5VQ
|
Triapine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Triapine
|
DCT082D
|
Triapine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Triapine
|
DCEYXXH
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
SY-1425 + Triapine
|
DC5S843
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
SY-1425 + Triapine
|
DCZZVM5
|
Triapine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Topetecan
|
DCL7S6G
|
Topetecan
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Topetecan
|
DC0HM0C
|
Topetecan
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Pralatrexate
|
DCK07QP
|
Pralatrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Pralatrexate
|
DCG4YN6
|
Pralatrexate
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + Terameprocol
|
DCSN8T0
|
Terameprocol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Terameprocol
|
DCE49JO
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Terameprocol
|
DCAYAR2
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
SY-1425 + Terameprocol
|
DC9OIZJ
|
Terameprocol
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
SY-1425 + Terameprocol
|
DCK9XX9
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Terameprocol
|
DCSFEFK
|
Terameprocol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SY-1425 + Terameprocol
|
DC9AKQ7
|
Terameprocol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
SY-1425 + Terameprocol
|
DCTGDSH
|
Terameprocol
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Terameprocol
|
DCN4GSL
|
Terameprocol
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + SCH 727965
|
DC97LFY
|
SCH 727965
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + SCH 727965
|
DC8XE4Z
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
SY-1425 + Ifosfamide
|
DC98KZP
|
Ifosfamide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
SY-1425 + Docetaxel
|
DCJ12EK
|
Docetaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Docetaxel
|
DCC2YML
|
Docetaxel
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
SY-1425 + Docetaxel
|
DCHYXGA
|
Docetaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Docetaxel
|
DC52BTU
|
Docetaxel
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Docetaxel
|
DCJYFB2
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Docetaxel
|
DCHC3PZ
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
SY-1425 + Docetaxel
|
DCQK6JZ
|
Docetaxel
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Docetaxel
|
DCKU98Z
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Docetaxel
|
DCR78CI
|
Docetaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
SY-1425 + Docetaxel
|
DCOF830
|
Docetaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Docetaxel
|
DCAH8VO
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Docetaxel
|
DCE1G93
|
Docetaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Docetaxel
|
DCKMF5J
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
SY-1425 + Docetaxel
|
DCNMOSH
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
SY-1425 + Docetaxel
|
DCGMGB5
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
SY-1425 + Docetaxel
|
DC4MXNY
|
Docetaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SY-1425 + Docetaxel
|
DCYNU9Q
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
SY-1425 + Docetaxel
|
DCAAULM
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
SY-1425 + Docetaxel
|
DCF5W8G
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Docetaxel
|
DCOOYOU
|
Docetaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
SY-1425 + Docetaxel
|
DC6ZQYH
|
Docetaxel
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Docetaxel
|
DCUN3GK
|
Docetaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
SY-1425 + Docetaxel
|
DC5XVFL
|
Docetaxel
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Docetaxel
|
DCMQZOQ
|
Docetaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
SY-1425 + Docetaxel
|
DCPK13U
|
Docetaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + Raloxifene
|
DCRQ2L8
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Raloxifene
|
DCW9GMN
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
SY-1425 + Raloxifene
|
DCPVXJ6
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
SY-1425 + Sirolimus
|
DCY694H
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Sirolimus
|
DCD2356
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Sirolimus
|
DCQU3BW
|
Sirolimus
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SY-1425 + Sirolimus
|
DC1UB77
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
SY-1425 + Sirolimus
|
DCHHGA9
|
Sirolimus
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Sirolimus
|
DC7BZYP
|
Sirolimus
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
SY-1425 + Mitomycin
|
DCCWQME
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Mitomycin
|
DCE1IJV
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Mitomycin
|
DC8L00U
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Altretamine
|
DC2BP0F
|
Altretamine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Altretamine
|
DCAKM5M
|
Altretamine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + TEM
|
DCR954W
|
TEM
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + TEM
|
DC80FIE
|
TEM
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
SY-1425 + TEM
|
DCYFHO6
|
TEM
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Idarubicin
|
DCV2PN5
|
Idarubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
SY-1425 + Idarubicin
|
DCNNJKT
|
Idarubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Idarubicin
|
DCD6OLK
|
Idarubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
SY-1425 + Imatinib
|
DCZKTVJ
|
Imatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
SY-1425 + Imatinib
|
DCZ5SCR
|
Imatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Bortezomib
|
DCC9Y88
|
Bortezomib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Valrubicin
|
DCO10C3
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Valrubicin
|
DC7Y7N0
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
SY-1425 + Valrubicin
|
DCMT95V
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Cisplatin
|
DC6TIZ8
|
Cisplatin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
SY-1425 + Chlorambucil
|
DCOW8BR
|
Chlorambucil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Chlorambucil
|
DCH409P
|
Chlorambucil
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Chlorambucil
|
DCKM2K1
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
SY-1425 + Chlorambucil
|
DCW1X1L
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
SY-1425 + Chlorambucil
|
DCOY7KB
|
Chlorambucil
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
SY-1425 + Sorafenib
|
DCFQI14
|
Sorafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Sorafenib
|
DCQ879E
|
Sorafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
SY-1425 + Sorafenib
|
DCNXRGP
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Sorafenib
|
DCUT485
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Sorafenib
|
DCJ3MW0
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
SY-1425 + Sorafenib
|
DCOAYAL
|
Sorafenib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Sorafenib
|
DCPY8OD
|
Sorafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Sorafenib
|
DCDB5Z9
|
Sorafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
SY-1425 + Sorafenib
|
DCQR7BS
|
Sorafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Sorafenib
|
DC7PDZ1
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
SY-1425 + Sorafenib
|
DCDZB03
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
SY-1425 + Sorafenib
|
DCZNQ9H
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
SY-1425 + Sorafenib
|
DCQT1RP
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
SY-1425 + Sorafenib
|
DCTGDMW
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
SY-1425 + Sorafenib
|
DCMQMV2
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SY-1425 + Sorafenib
|
DC2YUPY
|
Sorafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
SY-1425 + Sorafenib
|
DCID5RW
|
Sorafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
SY-1425 + Sorafenib
|
DC2GSRR
|
Sorafenib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
SY-1425 + Sorafenib
|
DCNJIUK
|
Sorafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
SY-1425 + Sorafenib
|
DCIWW5M
|
Sorafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Sorafenib
|
DCF7PLC
|
Sorafenib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
SY-1425 + Sorafenib
|
DCH20XY
|
Sorafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + ER819762
|
DCT8LGX
|
ER819762
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + ER819762
|
DCHQY7Z
|
ER819762
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + ER819762
|
DCXGV22
|
ER819762
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Azacitidine
|
DCUO7VZ
|
Azacitidine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Pomalidomide
|
DCCC91R
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Pomalidomide
|
DC1OP75
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Vinflunine
|
DC7IB28
|
Vinflunine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
SY-1425 + Vinflunine
|
DC5X5PH
|
Vinflunine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
SY-1425 + Vinflunine
|
DCGHP7R
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
SY-1425 + Vinflunine
|
DCUJYGX
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
SY-1425 + Vinflunine
|
DC934VJ
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
SY-1425 + Vinflunine
|
DC5FO64
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
SY-1425 + Vinflunine
|
DCED3UH
|
Vinflunine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
SY-1425 + Vinflunine
|
DCVQRWN
|
Vinflunine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Vinflunine
|
DCE77KE
|
Vinflunine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
SY-1425 + Taxol
|
DCAA956
|
Taxol
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Taxol
|
DCCN6KQ
|
Taxol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Taxol
|
DCA89CV
|
Taxol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
SY-1425 + Taxol
|
DCG9FXT
|
Taxol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SY-1425 + Taxol
|
DCS6OK2
|
Taxol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
SY-1425 + Taxol
|
DCX9A17
|
Taxol
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Taxol
|
DCDX22C
|
Taxol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
SY-1425 + Taxol
|
DCKS9T0
|
Taxol
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
SY-1425 + PMID28870136-Compound-43
|
DCSASP4
|
PMID28870136-Compound-43
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
SY-1425 + Aminolevulinic Acid Hydrochloride
|
DCTA11M
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
SY-1425 + Aminolevulinic Acid Hydrochloride
|
DC55UYM
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
SY-1425 + Estramustine
|
DCIAIFB
|
Estramustine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
SY-1425 + Busulfan
|
DC9NX6I
|
Busulfan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
SY-1425 + Busulfan
|
DCDZJPP
|
Busulfan
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Busulfan
|
DCPKWER
|
Busulfan
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
SY-1425 + Dasatinib
|
DC9XWF4
|
Dasatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
SY-1425 + Dasatinib
|
DCO4BQW
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
SY-1425 + Dasatinib
|
DCJS7RU
|
Dasatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Thioguanine + SY-1425
|
DC1M0RM
|
Thioguanine
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Thioguanine + SY-1425
|
DCUQGDE
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Thioguanine + SY-1425
|
DC51Z44
|
Thioguanine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Thioguanine + SY-1425
|
DCTM2QE
|
Thioguanine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Thioguanine + SY-1425
|
DCNZ2PH
|
Thioguanine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Topotecan + SY-1425
|
DCAE7XG
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Topotecan + SY-1425
|
DCGVY8E
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Topotecan + SY-1425
|
DCB5EJM
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Topotecan + SY-1425
|
DCNFOTE
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Topotecan + SY-1425
|
DCSERC3
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Topotecan + SY-1425
|
DCCOIK3
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Topotecan + SY-1425
|
DCC740M
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Topotecan + SY-1425
|
DCF9089
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Topotecan + SY-1425
|
DCIKAMH
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Topotecan + SY-1425
|
DCFMJ7K
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Topotecan + SY-1425
|
DCM7VUG
|
Topotecan
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Topotecan + SY-1425
|
DC5ZJES
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Topotecan + SY-1425
|
DCF5OWL
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Topotecan + SY-1425
|
DCJ614X
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Trifluridine + SY-1425
|
DCDT531
|
Trifluridine
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Trifluridine + SY-1425
|
DCPGK7B
|
Trifluridine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Trifluridine + SY-1425
|
DCSBDF5
|
Trifluridine
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Trifluridine + SY-1425
|
DCCR74V
|
Trifluridine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Trifluridine + SY-1425
|
DC906SI
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Uracil mustard + SY-1425
|
DCG571P
|
Uracil mustard
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vandetanib + SY-1425
|
DC2UXFS
|
Vandetanib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vandetanib + SY-1425
|
DCZWPA5
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vandetanib + SY-1425
|
DCHISNA
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vandetanib + SY-1425
|
DCLZLYI
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vandetanib + SY-1425
|
DCV7334
|
Vandetanib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vandetanib + SY-1425
|
DCP1B4R
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vandetanib + SY-1425
|
DCF7QU4
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vandetanib + SY-1425
|
DCX9MYL
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vemurafenib + SY-1425
|
DCA0WQ6
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Vemurafenib + SY-1425
|
DCN5NOW
|
Vemurafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vemurafenib + SY-1425
|
DC2MWY3
|
Vemurafenib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vemurafenib + SY-1425
|
DCOY3XQ
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vemurafenib + SY-1425
|
DCVKSKH
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vemurafenib + SY-1425
|
DCHPZ1D
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Vemurafenib + SY-1425
|
DCDACK7
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vemurafenib + SY-1425
|
DCC61HU
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vemurafenib + SY-1425
|
DCZ1ICY
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Vincristine + SY-1425
|
DC1ETZF
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Vincristine + SY-1425
|
DCA6IDN
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
Vincristine + SY-1425
|
DCP883V
|
Vincristine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Vincristine + SY-1425
|
DCU630R
|
Vincristine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Vismodegib + SY-1425
|
DC47ESM
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Vismodegib + SY-1425
|
DC64GFT
|
Vismodegib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Vismodegib + SY-1425
|
DC3K6RB
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vismodegib + SY-1425
|
DC20KFI
|
Vismodegib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vismodegib + SY-1425
|
DC9SCRX
|
Vismodegib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vismodegib + SY-1425
|
DCY4JSZ
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vismodegib + SY-1425
|
DCI34HU
|
Vismodegib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Vismodegib + SY-1425
|
DCHUDOA
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vismodegib + SY-1425
|
DCQZPQM
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vismodegib + SY-1425
|
DC5RESX
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vismodegib + SY-1425
|
DCSA2CS
|
Vismodegib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Vismodegib + SY-1425
|
DC8YA03
|
Vismodegib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
